AU2001249067A1 - Method of use of peptide antagonists of zonulin to prevent or delay the onset ofdiabetes - Google Patents

Method of use of peptide antagonists of zonulin to prevent or delay the onset ofdiabetes

Info

Publication number
AU2001249067A1
AU2001249067A1 AU2001249067A AU4906701A AU2001249067A1 AU 2001249067 A1 AU2001249067 A1 AU 2001249067A1 AU 2001249067 A AU2001249067 A AU 2001249067A AU 4906701 A AU4906701 A AU 4906701A AU 2001249067 A1 AU2001249067 A1 AU 2001249067A1
Authority
AU
Australia
Prior art keywords
onset
ofdiabetes
zonulin
delay
prevent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001249067A
Other languages
English (en)
Inventor
Alessio Fasano
Tammara L. Watts
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Maryland Baltimore
Original Assignee
University of Maryland Baltimore
University of Maryland College Park
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Maryland Baltimore, University of Maryland College Park filed Critical University of Maryland Baltimore
Publication of AU2001249067A1 publication Critical patent/AU2001249067A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4705—Regulators; Modulating activity stimulating, promoting or activating activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/827—Proteins from mammals or birds
    • Y10S530/843—Digestive system
    • Y10S530/844—Stomach; intestine

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Diabetes (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Nutrition Science (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
AU2001249067A 2000-05-19 2001-03-21 Method of use of peptide antagonists of zonulin to prevent or delay the onset ofdiabetes Abandoned AU2001249067A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US20530500P 2000-05-19 2000-05-19
US60205305 2000-05-19
PCT/US2001/005825 WO2001089551A1 (en) 2000-05-19 2001-03-21 Method of use of peptide antagonists of zonulin to prevent or delay the onset of diabetes

Publications (1)

Publication Number Publication Date
AU2001249067A1 true AU2001249067A1 (en) 2001-12-03

Family

ID=22761653

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001249067A Abandoned AU2001249067A1 (en) 2000-05-19 2001-03-21 Method of use of peptide antagonists of zonulin to prevent or delay the onset ofdiabetes

Country Status (8)

Country Link
US (6) US7026294B2 (enExample)
EP (1) EP1282432B1 (enExample)
JP (3) JP2003534287A (enExample)
AT (1) ATE438405T1 (enExample)
AU (1) AU2001249067A1 (enExample)
CA (1) CA2409771C (enExample)
DE (1) DE60139466D1 (enExample)
WO (1) WO2001089551A1 (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6458925B1 (en) * 1998-08-03 2002-10-01 University Of Maryland, Baltimore Peptide antagonists of zonulin and methods for use of the same
WO2001089551A1 (en) * 2000-05-19 2001-11-29 University Of Maryland, Baltimore Method of use of peptide antagonists of zonulin to prevent or delay the onset of diabetes
AU2004259705B2 (en) * 2003-07-15 2009-04-23 University Of Maryland, Baltimore Agonist polypeptide of receptor for zot and zonulin
US20090176244A1 (en) * 2005-05-13 2009-07-09 Bai Julio Methods and compositions for the diagnosis of crohn's disease
TW200716159A (en) * 2005-06-09 2007-05-01 Univ Maryland Method of use of antagonists of zonulin to prevent the loss of or to regenerate pancreatic cells
CN101420850A (zh) * 2006-02-09 2009-04-29 阿尔巴医疗公司 紧密连接效应子的制剂
AU2012203787B2 (en) * 2006-02-09 2014-07-10 Alba Therapeutics Corporation Formulations for a Tight Junction Effector
WO2008043107A2 (en) * 2006-10-06 2008-04-10 Alba Therapeutics Corporation Use of tight junction antagonists to treat inflammatory bowel disease
WO2008052185A2 (en) * 2006-10-26 2008-05-02 Alba Therapeutics Corp Materials and methods for the treatment of celiac disease
EP2091551B1 (en) * 2006-11-03 2020-01-15 Alba Therapeutics Corporation Method of treating asthma
AT504214B1 (de) * 2007-01-03 2008-04-15 Bernhard Hans Peter Dipl Ing D Verfahren zur dynamischen, datenabhängigen bestimmung und anwendung von berechtigungen in hierarchischen und relationalen umgebungen
US8728491B2 (en) * 2007-05-07 2014-05-20 Alba Therapeutics Corporation Transcutaneous delivery of therapeutic agents
US20110201543A1 (en) * 2007-06-29 2011-08-18 Blake Paterson Use of tight junction antagonists in the treatment of acute lung injury and acute respiratory distress
US8198233B2 (en) 2007-07-26 2012-06-12 Alba Therapeutics Corporation Synthetic peptides that enhance tight junction permeability
US9051349B2 (en) 2007-11-21 2015-06-09 Alba Therapeutics Corporation Larazotide acetate compositions
EP2062909A1 (en) 2007-11-21 2009-05-27 SOLVAY (Société Anonyme) Peptide production and purification process
WO2009137436A2 (en) * 2008-05-05 2009-11-12 Alba Therapeutics Corporation Peptide conjugates
US8957032B2 (en) 2008-05-06 2015-02-17 Alba Therapeutics Corporation Inhibition of gliadin peptides
US20190358288A1 (en) 2017-02-10 2019-11-28 Innovate Biopharmaceuticals, Inc. Compositions and methods for treating or preventing environmental enteropathy
KR20180107341A (ko) * 2017-03-16 2018-10-02 차의과학대학교 산학협력단 칼륨 경쟁적 위산분비억제제를 유효성분을 함유하는 장 누수 증후군 치료 및 예방용 조성물
WO2019165346A1 (en) 2018-02-23 2019-08-29 Innovate Biopharmaceuticals, Inc. Compounds and methods for treating tight junction permeability
US20210069286A1 (en) * 2018-04-09 2021-03-11 9 Meters Biopharma, Inc. Compositions and methods for treating or preventing hyperglycemia, insulin resistance, and associated organ damage

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5936065A (en) * 1993-12-06 1999-08-10 Cytel Corporation CS-1 peptidomimetics, compositions and methods of using the same
ES2168456T3 (es) * 1995-01-16 2002-06-16 North Sydney Area Health Serv Peptidos que afectan a los linfocitos t.
US5665389A (en) * 1995-05-24 1997-09-09 University Of Maryland At Baltimore Oral dosage composition for intestinal delivery and method of treating diabetes
ATE408617T1 (de) * 1996-06-11 2008-10-15 Northern Sydney And Central Co T zell antigen rezeptor peptide
US5945510A (en) * 1997-05-21 1999-08-31 University Of Maryland, Baltimore Substantially pure zonulin, a physiological modulator of mammalian tight junctions
US6458925B1 (en) 1998-08-03 2002-10-01 University Of Maryland, Baltimore Peptide antagonists of zonulin and methods for use of the same
WO2001089551A1 (en) * 2000-05-19 2001-11-29 University Of Maryland, Baltimore Method of use of peptide antagonists of zonulin to prevent or delay the onset of diabetes
US7025294B2 (en) * 2003-05-20 2006-04-11 Carter Day International, Inc. Hammermill with stub shaft rotor apparatus and method
CN101420850A (zh) * 2006-02-09 2009-04-29 阿尔巴医疗公司 紧密连接效应子的制剂
WO2008043107A2 (en) * 2006-10-06 2008-04-10 Alba Therapeutics Corporation Use of tight junction antagonists to treat inflammatory bowel disease
WO2008052185A2 (en) * 2006-10-26 2008-05-02 Alba Therapeutics Corp Materials and methods for the treatment of celiac disease

Also Published As

Publication number Publication date
ATE438405T1 (de) 2009-08-15
US20060128626A1 (en) 2006-06-15
US8183211B2 (en) 2012-05-22
WO2001089551A1 (en) 2001-11-29
EP1282432A4 (en) 2005-06-08
US20140128321A1 (en) 2014-05-08
EP1282432A1 (en) 2003-02-12
US20050065074A1 (en) 2005-03-24
CA2409771C (en) 2008-12-02
DE60139466D1 (de) 2009-09-17
CA2409771A1 (en) 2001-11-29
EP1282432B1 (en) 2009-08-05
US7531512B2 (en) 2009-05-12
US20080269136A1 (en) 2008-10-30
JP2011213742A (ja) 2011-10-27
JP2008074869A (ja) 2008-04-03
US20100087380A1 (en) 2010-04-08
JP2003534287A (ja) 2003-11-18
US20130157943A1 (en) 2013-06-20
US7026294B2 (en) 2006-04-11

Similar Documents

Publication Publication Date Title
AU2001249067A1 (en) Method of use of peptide antagonists of zonulin to prevent or delay the onset ofdiabetes
PL327146A1 (en) Antagonists of the gonadotrophin liberating hormone
HUP0103321A3 (en) Peptide antagonists of zonulin and methods for use of the same
ZA9710246B (en) Novel heterocycles as inhibitors of leucocyte adhesion and as VLA-4 antagonists.
AU5878601A (en) Structure for preventing loosening of threaded fasteners
AU4525797A (en) Heterocycles as inhibitors of leucocyte adhesion and as VLA-4 antagonists
AU4515997A (en) 5-membered ring heterocycles as inhibitors of leucocyte adhesion and as VLA-4 antagonists
IL161121A0 (en) Copolymers for suppression of autoimmune diseases, and methods of use
AU5025300A (en) Compositions for controlled release of the hormone gnrh and its analogs
AU2001285318A1 (en) Use of an aldosterone receptor antagonist to improve cognitive function
AU2003298911A1 (en) Cyclosporins for the treatment of autoimmune diseases
AU2001233029A1 (en) Blend for preventing or retarding the formation of gas hydrates
CA2270423A1 (en) Prophylactic/therapeutic agent
EP0916344A3 (en) Nef action inhibitor
AU6902901A (en) Synchronisation of databases
AU2002216847A1 (en) Epitopes of pai-1
NO20001548D0 (no) Endotelinantagonist og en renin-angiotensinsystem inhibitor som et kombinert preparat
AU2000265516A1 (en) Compositions and methods for inhibiting islet dysfunction and autoimmune disorders
AU1929401A (en) Method for screening non-peptide, non-steroid inverterbrate pheromones, compositions containing the same and use of the compositions to treat diseases, conditions, and symptoms thereof
CA95790S (en) Lavatory
WO2001059076A3 (en) Premeiotic and postmeiotic origin of teratomas: isolated teratoma stem cells for therapeutic uses
AU2001271281A1 (en) Novel compositions for the expression of the human peptide histidine transporter1 and methods of use thereof
WO2002016432A3 (en) Two receptors of meiosis activating sterols designated sam1a and sam1b
AU2002223703A1 (en) Prevention of development of dyskinesias
WO2002016433A3 (en) Two receptors of meiosis activating sterols designated sam1a and sam1b